Saturday 17 October 2026 Export IRTC’s income statement to Excel — free account

iRhythm Holdings, Inc.

iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS grew 97.7%, free cash flow grew 117.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

108.66 0.69 −0.63%

Follow IRTC

Alert me

Market cap: $3.6B
P/E: 0.0×
Fwd P/E: −1,660×
Dividend yield: —
F-score: 5/9
Altman Z: 4.02
Beneish M: −3.04
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.06

Total sells 27.35

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	1	—	—	—	—	—
Sell	2	2	—	11	9	—	1	2	2	8	1	—

Insider Ownership 1.90%

Capital & Financial Ratios $m

Market Cap 3,600.00

Revenue 825.34

Net Income (13.95)

Free Cash Flow 38.98

Net Debt 59.82

Current Ratio 3.86

Debt/Equity 3.50

P/E ratio 0.00

Fwd P/E (1,660.00)

P/S ratio 4.33

P/B ratio 19.22

Past 5Y EPS Growth —

This Y EPS Growth 85.16%

Next Y EPS Growth 662.86%

Next Y revenue growth 19.26%

Next 5Y EPS Growth 40.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 7.77%

10-year low 10-year high

P/B against its own 10 years 52.50%

10-year low 10-year high

EV/Sales against its own 10 years 8.76%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	134	536	584	591
Receivables	61	80	76	84
Inventory	14	14	22	23
Other	—	—	—	—
	231	646	703	756

	2023	2024	2025	Q'26
Payables	6	7	2	17
ST’ Debt	—	—	—	—
Other	—	—	—	—
	107	111	152	196

Compound Annual Growth %

	10y	5y	3y
Sales	35.38%	23.02%	22.05%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(14.87%)	(13.96%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	199	224	—	—	—
’25	159	187	193	209	747
’24	132	148	148	164	592
’23	111	124	125	133	493
’22	92	102	104	113	411
’21	74	81	85	82	323
’20	64	51	72	79	265

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	51	—	—	—
’25	(8)	28	35	26	81
’24	(52)	12	24	19	3
’23	(31)	(5)	1	(16)	(50)
’22	(39)	0	4	13	(23)
’21	(42)	(1)	18	(13)	(38)
’20	(22)	(10)	11	8	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(33)	38	—	—	—
’25	(17)	17	20	14	35
’24	(62)	3	1	12	(46)
’23	(39)	(14)	(8)	(29)	(91)
’22	(44)	(11)	(3)	5	(53)
’21	(46)	(6)	4	(18)	(66)
’20	(26)	(12)	5	5	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.43)	(0.01)	—	—	—
’25	(0.97)	(0.44)	(0.16)	0.17	(1.39)
’24	(1.47)	(0.65)	(1.48)	(0.04)	(3.63)
’23	(1.29)	(0.61)	(0.89)	(1.26)	(4.04)
’22	(1.71)	(0.80)	(0.71)	(0.67)	(3.88)
’21	(0.95)	(0.59)	(0.81)	(1.10)	(3.46)
’20	(0.34)	(0.75)	(0.17)	(0.33)	(1.58)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	22.16	28.70	55.18	56.24	56.54	41.66	88.73	70.24	55.92	86.55	Analyst estimates 2026–2028 Powerpack
	High	31.69	57.91	98.37	98.13	274.21	286.19	169.54	140.23	124.12	212.00
People
People	Employees	406	575	748	997	1,157	1,700	1,793	2,000	2,000	2,400
	Revenue/emp, $m	0.16	0.17	0.20	0.22	0.23	0.19	0.23	0.25	0.30	0.31
Income, $m
Income, $m	Revenue	64	99	147	215	265	323	411	493	592	747
	Gross margin, %	67.41	71.55	73.66	75.54	73.50	66.16	68.54	67.35	68.86	70.57
	EBT	(21)	(30)	(50)	(55)	(44)	(101)	(116)	(123)	(113)	(44)
	EBT margin, %	(32.62)	(30.00)	(34.18)	(25.40)	(16.44)	(31.28)	(28.20)	(24.90)	(19.05)	(5.84)
	Net income	(21)	(30)	(50)	(55)	(44)	(101)	(116)	(123)	(113)	(45)
	Depreciation	1	2	2	3	7	11	19	17	27	26
Per share, $
Per share, $	Revenue	12.12	4.38	6.17	8.49	9.55	11.01	13.74	16.14	18.97	23.35
	Earnings	(3.95)	(1.30)	(2.02)	(2.16)	(1.58)	(3.46)	(3.88)	(4.04)	(3.63)	(1.39)
	Cash flow	(3.15)	(0.66)	(1.22)	(0.87)	(0.50)	(1.29)	(0.77)	(1.64)	0.11	2.53
	Capex	(0.52)	(0.16)	(0.22)	(0.81)	(0.49)	(0.96)	(1.00)	(1.32)	(1.57)	(1.45)
	Free cash flow	(3.67)	(0.82)	(1.43)	(1.67)	(0.98)	(2.24)	(1.77)	(2.97)	(1.46)	1.08
	Book value	17.51	3.52	2.18	5.36	12.31	9.53	8.02	6.88	2.91	4.77
	Shares, m	5	23	24	25	28	29	30	31	31	32
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.47	13.14	11.27	8.02	24.83	10.69	6.85	6.28	4.75	7.60
	P/B	1.71	16.38	31.83	12.70	19.27	12.35	11.74	14.73	30.94	37.18
	EV/Sales	1.32	12.45	10.98	7.53	23.69	10.02	6.44	6.10	4.96	7.70
	EV/FCF	(4.36)	(66.83)	(47.20)	(38.16)	(230.00)	(49.14)	(50.11)	(33.21)	(96.08)	166.74
Cash, $m
Cash, $m	Operating cash flow	(17)	(15)	(29)	(22)	(14)	(38)	(23)	(50)	3	81
	Capex	(3)	(4)	(5)	(20)	(14)	(28)	(30)	(40)	(49)	(46)
	Free cash flow	(19)	(18)	(34)	(42)	(27)	(66)	(53)	(91)	(46)	35
Balance, $m
Balance, $m	Working capital	105	99	74	121	312	218	200	123	535	551
	Total debt	32	34	35	35	33	21	35	35	646	650
	Net debt	(74)	(68)	(43)	(106)	(302)	(218)	(178)	(99)	111	66
	Shareholders’ equity	93	80	52	135	342	280	240	210	91	153
Returns, %
Returns, %	ROA	(23.75)	(21.93)	(40.20)	(25.76)	(10.72)	(20.80)	(25.50)	(28.00)	(16.60)	(4.57)
	ROIC	(52.22)	(154.41)	(328.50)	(114.87)	(69.28)	(101.17)	(115.44)	(70.29)	(35.77)	(16.42)
	ROE	461.33	(34.56)	(76.51)	(58.19)	(18.38)	(32.64)	(44.73)	(54.86)	(75.27)	(36.57)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HAE Haemonetics Corporation	$5.5B	57.7×	18.0×	+5.60% (above 0%: growing)	+2.86% (above 0%: growing)	+220.38% (above 0%: growing)	59.76%	16.93%	Compare
LIVN LivaNova PLC	$4.3B	22.5×	26.0×	+10.80% (above 0%: growing)	+296.00% (above 0%: growing)	−26.66% (below 0%: shrinking)	70.07%	12.67%	Compare
ITGR Integer Holdings Corporation	$4.3B	34.3×	27.6×	−2.60% (below 0%: shrinking)	−34.91% (below 0%: shrinking)	+48.81% (above 0%: growing)	24.34%	7.44%	Compare
IRTC iRhythm Holdings, Inc.	$3.6B	— (loss-making)	— (loss-making)	+20.08% (above 0%: growing)	n/m	+116.98% (above 0%: growing)	72.80%	(1.13%)
NEOG Neogen Corporation	$2.7B	— (loss-making)	— (loss-making)	+6.51% (above 0%: growing)	n/m	+135.75% (above 0%: growing)	47.35%	(0.81%)	Compare
TMDX TransMedics Group, Inc.	$2.7B	16.0×	34.1×	+20.70% (above 0%: growing)	−59.22% (below 0%: shrinking)	−87.62% (below 0%: shrinking)	59.59%	12.50%	Compare
UFPT UFP Technologies, Inc.	$2.3B	31.2×	23.6×	+15.07% (above 0%: growing)	+20.63% (above 0%: growing)	−35.77% (below 0%: shrinking)	29.27%	16.15%	Compare
BFLY Butterfly Network, Inc.	$2.1B	— (loss-making)	— (loss-making)	+39.47% (above 0%: growing)	n/m	−113.85% (below 0%: shrinking)	71.41%	(41.90%)	Compare
AXGN AxoGen, Inc.	$2.1B	— (loss-making)	— (loss-making)	+23.06% (above 0%: growing)	n/m	−17.36% (below 0%: shrinking)	72.67%	(3.09%)	Compare
Median of peers	$2.7B	31.2×	26.0×	+12.94%	+2.86%	−22.01%	59.68%	9.97%

All 149 Medical Devices stocks →

iRhythm Holdings, Inc. (IRTC) key facts

Concern: iRhythm Holdings, Inc. reported a net loss of $44.6 million, or a loss of $1.39 per share, for fiscal 2025.
Strength: iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
iRhythm Holdings, Inc. (IRTC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IRTC traded at $108.66, a market capitalization of $3.6 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.3× sales.
Return on equity was −36.6% and debt-to-equity 3.50.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.02 (safe zone) for fiscal 2025.